* Amphastar Pharmaceuticals Inc AMPH.OQ AMPH.O is
expected
to show a rise in quarterly revenue when it reports results on
August 8.
* The Rancho Cucamonga California-based company is expected
to
report a 11.3% increase in revenue to $137.368 million from
$123.47 million a year ago, according to the mean estimate from
4 analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Amphastar
Pharmaceuticals
Inc is for earnings of 56 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Amphastar
Pharmaceuticals Inc is $66, above its last closing price
of $62.81.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 0.47 0.48 0.62 Beat 30.4
Dec. 31 2023 0.40 0.41 0.73 Beat 79.7
Sep. 30 2022 0.40 0.39 0.38 Missed -3.6
Jun. 30 2022 0.35 0.35 0.39 Beat 12.1
Mar. 0.36 0.36 0.47 Beat 30.6
31 2022
Dec. 31 2021 0.33 0.36 0.42 Beat 16.1
Sep. 30 2021 0.25 0.24 0.46 Beat 89
Jun. 30 2021 0.22 0.21 0.21 Met 0.8
This summary was machine generated August 5 at 00:49 GMT. All
figures in US dollars unless otherwise stated